Latest news

CommercialJuly 30, 2026

GSK will increase its R&D efforts by investing £400 million in Britain over three years

British pharmaceutical and biotechnology firm GSK has announced a comprehensive investment plan in the United Kingdom's pharmaceutical and biotechnology...

ClinicalJuly 30, 2026

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Hansoh Pharmaceutical has recorded another late-stage success for its B7-H3-targeting antibody-drug conjugate (ADC), developed in partnership with GSK, after...

ClinicalJuly 28, 2026

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Altimmune has reported topline results from its Phase 2 RECLAIM trial evaluating pemvidutide, an investigational dual GLP-1/GIP receptor agonist,...

CommercialJuly 28, 2026

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

Virtual care and health navigation company Included Health has agreed to acquire Firefly Health as it seeks to scale...

CommercialJuly 27, 2026

Argenx purchases Forte for $2.2 billion to enter the hands-on phase two-stage medication for vitiligo

Forte Biosciences is being acquired by Argenx for $2.2...

InsightsJuly 27, 2026

What Pharma Leaders Are Prioritizing in 2026

Executive Summary The pharmaceutical industry is entering a new phase...

RegulatoryJuly 26, 2026

Takeda’s Qdenga Makes History as First Vaccine to Get the Nod in India

Takeda has secured approval from the Drug Controller General of India (DCGI) for Qdenga, making it the first vaccine...

CommercialJuly 26, 2026

Tempus purchases a specialist in cancer genomics in a $1.5 billion deal: Personalis

Since the two first joined forces in oncology three years ago, Tempus is expanding its cancer programs with plans...

InsightsJuly 26, 2026

How RNA Therapeutics Are Expanding Beyond Rare Diseases

Executive Summary RNA therapeutics have emerged as one of the most significant innovations in modern medicine. Initially developed to address rare...

CommercialJuly 26, 2026

Samsung Biologics Plans $1.8 Billion Acquisition of PolyPeptide

Samsung Biologics has announced plans to acquire Swiss contract...

ClinicalJuly 26, 2026

Sanofi Ends Amlitelimab Development in Atopic Dermatitis After Phase 3 Program Review

Sanofi has decided to stop pursuing amlitelimab for atopic...

RegulatoryJuly 26, 2026

Amgen Submits FDA Hearing Request to Defend Tavneos for ANCA-Associated Vasculitis

Amgen has submitted a package of data and analyses to the U.S. Food and Drug Administration (FDA) as part...

ClinicalJuly 25, 2026

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Johnson & Johnson has reported striking Phase 3 results for its dual bispecific antibody regimen in earlier-line multiple myeloma,...

UncategorizedJuly 25, 2026

Top 10 Reasons Drug Development Timelines Remain Difficult to Compress

Executive Summary The pharmaceutical industry has made remarkable advances in accelerating drug development. Artificial intelligence (AI), decentralized clinical trials, real-world...